Aristides Capital’s BioNTech BNTX Stock Holding History

Aristides Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1M	Buy	10,790 +790	+8%	+$74.3K	0.2%	102
2026 Q1	$889K	Sell	10,000 -16,559	-62%	-$1.7M	0.19%	86
2025 Q4	$2.53M	Buy	26,559 +1,200	+5%	+$121K	0.45%	45
2025 Q3	$2.5M	Buy	25,359 +8,000	+46%	+$855K	0.36%	48
2025 Q2	$1.85M	Buy	17,359 +2,826	+19%	+$285K	0.37%	44
2025 Q1	$1.32M	Sell	14,533 -3,477	-19%	-$389K	0.39%	55
2024 Q4	$2.05M	Buy	18,010 +6,110	+51%	+$697K	0.42%	42
2024 Q3	$1.41M	Hold	11,900	–	–	0.44%	50
2024 Q2	$956K	Hold	11,900	–	–	0.27%	79
2024 Q1	$1.1M	Hold	11,900	–	–	0.4%	66
2023 Q4	$1.26M	Buy	11,900 +10,000	+526%	+$1.01M	0.46%	49
2023 Q3	$206K	Hold	1,900	–	–	0.09%	131
2023 Q2	$205K	Hold	1,900	–	–	0.08%	131
2023 Q1	$237K	Hold	1,900	–	–	0.13%	109
2022 Q4	$285K	Buy	+1,900	New	+$292K	0.15%	111

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Aristides Capital's BNTX Position: Q2 2026 in Review

Aristides Capital increased its BioNTech (BNTX) stake by 7.9% in Q2 2026, buying an estimated $74.3K and bringing the position to 10,790 shares worth $1M. The position accounts for 0.2% of the portfolio, ranked #102.

Aristides Capital first reported a position in BNTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $2.53M in Q4 2025. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Aristides Capital held 10,790 shares of BioNTech worth $1M as of Q2 2026.
Aristides Capital bought 790 BioNTech shares in Q2 2026, an estimated $74.3K.
BioNTech made up 0.2% of Aristides Capital's portfolio in Q2 2026, its #102 holding.
Aristides Capital first reported a position in BioNTech in Q4 2022 and has held it in 15 quarters since.
Aristides Capital's BioNTech position peaked at $2.53M in Q4 2025.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Aristides Capital's 13F filing for Q2 2026, filed 13 Aug 2026.